WO1994014455A1 - Bisphosphonate/estrogen therapy for treating and preventing bone loss - Google Patents

Bisphosphonate/estrogen therapy for treating and preventing bone loss Download PDF

Info

Publication number
WO1994014455A1
WO1994014455A1 PCT/US1993/012302 US9312302W WO9414455A1 WO 1994014455 A1 WO1994014455 A1 WO 1994014455A1 US 9312302 W US9312302 W US 9312302W WO 9414455 A1 WO9414455 A1 WO 9414455A1
Authority
WO
WIPO (PCT)
Prior art keywords
bisphosphonate
estrogen
bone
bone loss
composition
Prior art date
Application number
PCT/US1993/012302
Other languages
French (fr)
Inventor
Donna T. Whiteford
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to JP6515312A priority Critical patent/JPH08505142A/en
Priority to AU59538/94A priority patent/AU5953894A/en
Priority to EP94905419A priority patent/EP0675723A4/en
Publication of WO1994014455A1 publication Critical patent/WO1994014455A1/en
Priority to US08/880,735 priority patent/US6399592B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the instant invention relates generally to the combination of estrogen and bisphosphonates and their use in bone growth and maturation. Specifically, the invention relates to the use of estrogen and bisphosphonates to inhibit bone reso ⁇ tion and promote net bone formation. This therapeutic combination will result in a decreased rate of bone reso ⁇ tion with either an increase or stabilization of bone mass.
  • the normal bones are living tissues undergoing constant reso ⁇ tion and redeposition of calcium, with the net effect of maintenance of a constant mineral balance.
  • the dual process is commonly called "bone turnover".
  • the mineral deposition exceeds the mineral reso ⁇ tion
  • bone reso ⁇ tion exceeds bone deposition, for instance due to malignancy or primary hype ⁇ arathyroidism, or in osteoporosis.
  • the calcium deposition may take place in undesirable amounts and areas leading to e.g. heterotopic calcification, osteoarthritis, kidney or bladder stones, atherosclerosis, and Paget's disease which is a combination of an abnormal high bone reso ⁇ tion followed by an abnormal calcium deposition.
  • Bisphosphonates are also known in the art as bone reso ⁇ tion inhibitors.
  • Alendronate 4-amino- 1 -hydroxybutylidene- 1 ,1 - bisphosphonic acid monosodium trihydrate, is described as a composition, method of use and synthesis in US Patents 4,621 ,077 (Gentili); 4,922,007 and 5,019,651 (Merck).
  • Clodronate (dichloromethylene)bisphosphonic acid disodium salt (Proctor and Gamble, is described in Belgium Patent 672,205 (1966) and J. Org. Chem 32, 41 1 1 ( 1967) for its preparation.
  • Tiludronate ([(4-chlorophenyl)thiomethylene]- bisphosphonic acid) (Sanofi) is described in U.S. Patent 4,876,248 issued October 24, 1989.
  • YM 175 [(cycloheptylamino)methylene]bisphosphonic acid, disodium salt) by Yamanouchi is described in U.S. Patent 4,970,335 issued November 13, 1990.
  • a female patient is undergoing estrogen therapy for a menopausal or postmenopausal-related condition, (e.g., vasomotor symptoms, atrophy of the vaginal mucosa, increased cardiovascular risk, etc.) and is also discovered to be suffering from osteoporosis (i.e. rarefaction of bone) or to be at risk for developing osteoporosis.
  • a menopausal or postmenopausal-related condition e.g., vasomotor symptoms, atrophy of the vaginal mucosa, increased cardiovascular risk, etc.
  • osteoporosis i.e. rarefaction of bone
  • estrogens/hormone replacement therapy are known to help prevent the development of osteoporosis, there are instances, which are not at all uncommon, where HRT or a weak estrogen is prescribed at dosages which do not provide adequate protection against osteoporosis. There are also some women who continue to lose bone mass despite treatment with higher estrogen/HRT doses or who have established osteoporosis but fail to increase their bone mass on estrogen/HRT alone.
  • the present invention discloses a combination method for treating and/or preventing bone loss in a subject by the combination therapy of pharmaceutically effective amounts of estrogen and of a bisphosphonate selected from: alendronate, clodronate, tiludronate, YM 175, BM 210995, or mixture thereof.
  • estradien as used herein is meant “17-beta estradiol” and includes those equivalent materials contained in the MERCK INDEX - Eleventh Edition (1989). Estrogens, e.g. estradiol and its steroidal and non-steroidal equivalents which can be used herein include (page numbers taken from the above indicated MERCK INDEX):
  • Estradiol 3653 Estradiol Benzoate, 3655 Estradiol 17 ⁇ -Cypionate, 3656 Estriol, 3659 Estrone, 3660 Ethinyl Estradiol, 3689 Mestranol, 5819 Moxestrol, 6203 Mytatrienediol, 6254 Progesterone, 7783 Quinestradiol, 8065 Quinestrol, 8066 and including estrogen/progestin combinations.
  • bisphosphonates as used herein is meant bisphosphonates of the structure:
  • Rl is OH or H and R2 is an C1 -C5 linear, branched or cyclic alkyl or alkylidene which can be substituted by an terminal amino, substituted amino, e.g. dimethylamino, methylamino, ethylamino, heterocyclic amino, and the like.
  • bisphosphonates are the bisphosphonates described above, and those in the US Patents 4,732,998; 4,870,063; 5,130,304 to Leo Pharmaceuticals. Excluded from this category is risedronate.
  • the method can be used to treat subjects in general, including sport, pet, and farm animals, and humans.
  • the term “inhibition of bone reso ⁇ tion” refers to prevention of bone loss, especially the inhibition of removal of existing bone either from the mineral phase and/or the organic matrix phase, through direct or indirect alteration of osteoclast formation or activity.
  • the term “inhibitor of bone reso ⁇ tion” as used herein refers to agents that prevent bone loss by the direct or indirect alteration of osteoclast formation or activity.
  • osteoogenically effective means that amount which effects the turnover of mature bone. As used herein, an osteogenically effective dose is also “pharmaceutically effective.”
  • subject refers to a living vertebrate animal such as a mammal or bird in need of treatment, i.e., in need of bone repair or replacement. Such need arises locally in cases of bone fracture, non-union, defect, prosthesis implantation, and the like. Such need also arises in cases of systemic bone disease, as in osteoporosis, osteoarthritis, Paget's disease, osteomalacia, multiple myeloma and other forms of cancer, steroid therapy, and age-related loss of bone mass. Particularly preferred is a human female subject.
  • treatment shall mean (1 ) providing a subject with an amount of a substance sufficient to act prophylactically to prevent the development of a weakened and/or unhealthy state; and/or (2) providing a subject with a sufficient amount of a substance so as to alleviate or eliminate a disease state and/or the symptoms of a disease state, and a weakened and/or unhealthy state.
  • Drugs which prevent bone loss and/or add back lost bone may be evaluated in the ovariectomized rat.
  • This animal model is well established in the art (see, for example, Wronski, et al. (1985) Calcif. Tissue Int. 37:324-328; Kimmel, et al. (1990) Calcif. Tissue Int. 46:101-1 10; and Durbridge, et al. (1990) Calcif. Tissue Int 47:383-387; these references are hereby inco ⁇ orated in their entirety).
  • Wronski, et al. ((1985) Calcif. Tissue Int. 43: 179-183)) describe the association of bone loss and bone turnover in the ovariectomized rat.
  • compositions of the invention which include a bone growth factor and/or an inhibitor of bone reso ⁇ tion for administration will generally include an osteogenically effective amount of the bone growth factor to promote bone growth, in addition to a pharmaceutically acceptable excipient.
  • Suitable excipients include most carriers approved for parenteral administration, including water, saline, Ringer's solution, Hank's solution, and solutions of glucose, lactose, dextrose, ethanol, glycerol, albumin, and the like.
  • These compositions may optionally include stabilizers, antioxidants, antimicrobials, preservatives, buffering agents, surfactants, and other accessory additives.
  • the inhibitor of bone reso ⁇ tion may also be delivered in a sustained release form from a suitable carrier.
  • a presently preferred vehicle comprises about 1 mg/ml serum albumin (species-specific) in phosphate-buffered saline (PBS) or isotonic citrate buffer.
  • PBS phosphate-buffered saline
  • isotonic citrate buffer phosphate-buffered saline
  • suitable vehicles for parenteral administration may be found in E. W. Martin. "Remington's Pharmaceutical Sciences” (Mack Pub. Co., current edition sections relating to the excipient vehicles and formulating being inco ⁇ orated herein by reference to disclose such).
  • Such formulations are generally known to those skilled in the art and are administered systemically to provide systemic treatment.
  • the estrogen and bisphosphonate may be administered sequentially or concurrently in separate dosages or as a single composition to the subject. If administered sequentially, the period between the administration of the estrogen and bisphosphonate will typically be one week to one year, and optimally, one week to six months.
  • the molar ratio of the estrogen and bisphosphonate will be about 50: 1 to 1 :50, preferably, 5:1 to 1 :5. The optimal ratio is expected to vary from compound to compound.
  • the estrogen and bisphosphonate may be separate components of the composition, or they may be conjugated to each other. Methods for conjugating bone growth factors to other agents are described above.
  • an effective dose of estrogen for systemic treatment will range from about 0.001 ⁇ g/kg to about 50 ⁇ g/kg of body weight and preferably about 30 ⁇ g/kg of body weight.
  • An effective dose for biphosphonate is about 1.5 to 3000 ⁇ g/kg of body weight and preferably about 10 ⁇ g/kg to about 200 ⁇ g/kg of body weight.
  • Effective doses for local administration would be about 0.001 ⁇ g to 1 mg per application site.
  • the methods and compositions of the invention are useful for treating bone fractures defects and disorders which result in weakened bones such as osteoporosis, osteoarthritis, Paget's disease, osteohalisteresis, osteomalacia, bone loss resulting from multiple myeloma other forms of cancer, bone loss resulting from side effects of other medical treatment (such as steroids), and age-related loss of bone mass.
  • weakened bones such as osteoporosis, osteoarthritis, Paget's disease, osteohalisteresis, osteomalacia
  • bone loss resulting from multiple myeloma other forms of cancer bone loss resulting from side effects of other medical treatment (such as steroids), and age-related loss of bone mass.
  • the estrogen and bisphosphonate may be administered systemically either orally and/or parenterally, including subcutaneous or intravenous injection. Additionally, the estrogen and bisphosphonate make be delivered in a slow release form from a suitable carrier.
  • the estrogen may be administered locally to a specific area in need of bone growth or repair, with either the concomitant administration of the bisphosphonate at the site, or the administration of the bisphosphonate in a separate vehicle, or the inhibitor of bone reso ⁇ tion may be provided locally with the administration of the estrogen in a separate vehicle.
  • the estrogen and/or bisphosphonate may be implanted directly at the site to be treated, for example, by injection or surgical implantation in a sustained-release carrier.
  • Suitable carriers include hydrogels, controlled- or sustained-release devices (e.g., an Alzet® minipump), polylactic acid, and collagen matrices.
  • telopeptide collagen containing particulate calcium phosphate mineral components such combinations of homologous or xenographic fibrillar atelopeptide collagen (for example Zyderm® Collagen Implant, available from Collagen Co ⁇ oration, Palo Alto, Calif.) with hydroxapatitetricalcium phosphate (HA-TCP, available from Zimmer, Inc., Warsaw, In.). It is presently preferred to administer implant compositions containing and/or an bisphosphonate in a collagen/mineral mixture implant.
  • Estrogen and/or an bisphosphonate delivered in sustained- release vehicles is also particularly useful for improving implant fixation, for example for improving in growth of new bone into a metal prosthesis in joint reconstruction and dental or orthopedic implants.
  • the estrogen may be delivered in the implant, with the bisphosphonate delivered in a separate vehicle, and vice-versa.
  • Dental and orthopedic implants can be coated with estrogen in combination with an bisphosphonate to enhance attachment of the implant device to the bone.
  • the estrogen can be used to coat the implant, and the bisphosphonate can be administered concomitantly or sequentially in a separate vehicle, and vice-versa.
  • implant devices may be coated with a estrogen and/or an bisphosphonate as follows.
  • the estrogen and the bisphosphonate if desired is dissolved at a concentration in the range of 0.01 ⁇ g/ml to 200 mg/ml in phosphate-buffered saline (PBS) containing 2 mg/ml serum albumin.
  • PBS phosphate-buffered saline
  • the porous end of an implant is dipped in the solution and is airdried (or lyophilized) or implanted immediately into the bony site.
  • the viscosity of the coating solution is increased, if desired, by adding hyaluronate at a final concentration of 0.1 mg/ml to 100 mg/ml or by adding other pharmaceutically acceptable excipients.
  • the solution containing the estrogen (and the bisphosphonate, if desired) is mixed with collagen gel or human collagen (e.g. Zyderm® Collagen Implant, Collagen Co ⁇ ., Palo alto, Calif.) to a final collagen concentration of 2 mg/ml to 100 mg/ml to form a paste or gel, which is then used to coat the porous end of the implant device.
  • collagen gel or human collagen e.g. Zyderm® Collagen Implant, Collagen Co ⁇ ., Palo alto, Calif.
  • the coated implant device is placed into the bony site immediately or is airdried and rehydrate with PBS prior to implanting, with the objective of maximizing new bone formation into the implant while minimizing the ingrowth of soft tissue into the implant site.
  • compositions according to the present invention containing, e.g., both alendronate and estradiol, may be prepared for use in the form of capsules or tablets or in solution for oral administration or for systemic use.
  • the compositions are advantageously prepared together with inert carriers such as sugars (saccharose, glucose, lactose), starch and derivatives, cellulose and derivatives, gums, fatty acids and their salts, polyalcohols, talc, aromatic esters.

Abstract

Disclosed is a combination therapy for treating and for preventing bone loss by the use of estrogen and a bisphosphonate selected from: alendronate, clodronate, tiludronate, YM175, BM210995, or mixture thereof. Also described is a pharmaceutical composition of the above for carrying out the therapeutic method.

Description

TITLE OF THE INVENTION
BISPHOSPHONATE/ESTROGEN THERAPY FOR TREATING AND
PREVENTING BONE LOSS
FIELD OF THE INVENTION
The instant invention relates generally to the combination of estrogen and bisphosphonates and their use in bone growth and maturation. Specifically, the invention relates to the use of estrogen and bisphosphonates to inhibit bone resoφtion and promote net bone formation. This therapeutic combination will result in a decreased rate of bone resoφtion with either an increase or stabilization of bone mass.
BACKGROUND OF THE INVENTION
The normal bones are living tissues undergoing constant resoφtion and redeposition of calcium, with the net effect of maintenance of a constant mineral balance. The dual process is commonly called "bone turnover". In normal growing bones, the mineral deposition exceeds the mineral resoφtion, whereas in certain pathological conditions, bone resoφtion exceeds bone deposition, for instance due to malignancy or primary hypeφarathyroidism, or in osteoporosis. In other pathological conditions the calcium deposition may take place in undesirable amounts and areas leading to e.g. heterotopic calcification, osteoarthritis, kidney or bladder stones, atherosclerosis, and Paget's disease which is a combination of an abnormal high bone resoφtion followed by an abnormal calcium deposition.
Most of the currently available therapeutic agents for the treatment of osteoporosis, e.g. estrogens, act by reducing bone resoφtion in the osteoporotic patient. See the review article, British Medical Bulletin 46 (1 ), p. 94-1 12 (1990).
Bisphosphonates are also known in the art as bone resoφtion inhibitors. Alendronate, 4-amino- 1 -hydroxybutylidene- 1 ,1 - bisphosphonic acid monosodium trihydrate, is described as a composition, method of use and synthesis in US Patents 4,621 ,077 (Gentili); 4,922,007 and 5,019,651 (Merck).
Clodronate, (dichloromethylene)bisphosphonic acid disodium salt (Proctor and Gamble, is described in Belgium Patent 672,205 (1966) and J. Org. Chem 32, 41 1 1 ( 1967) for its preparation.
Tiludronate, ([(4-chlorophenyl)thiomethylene]- bisphosphonic acid) (Sanofi) is described in U.S. Patent 4,876,248 issued October 24, 1989.
YM 175 ([(cycloheptylamino)methylene]bisphosphonic acid, disodium salt) by Yamanouchi is described in U.S. Patent 4,970,335 issued November 13, 1990.
BM 210995 (l -Hydroxy-3-(methylpentylamino)- propylidene-bisphosphonate) by Boehringer-Mannheim - is described in U.S. Patent 4,927,814 issued May 22, 1990.
A study by Proctor and Gamble (Norwich Eaton Pharmaceuticals) using risendronate, whose chemical name is sodium trihydrogen [ 1 -hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonate, in combination with estrogen showed a positive effect on bone loss in ovaricetomized rats (published in Abstracts 731 and 732 at the Fall 1992 ASBMR meeting in Minnesota.
The article, J. Clin. Invest., Jan. 1992, 89 (1 ), p. 74-78 by J. Chow et al., describes the effect of estrogen on ovariectomized rats in which bone resoφtion was suppressed by pamidronate. They concluded that estrogen inhibits bone resoφtion and also stimulates bone formation.
The article, J. Bone Miner. Res. (USA) 1991 , p. 387-394 by T.J. Wronski et al., describes studies in rats with estrogen and the bisphosphonates etidronate and risedronate. The studies showed that etidronate, (l-hydroxyethylidene)bisphosphonic acid, disodium salt, (Proctor and Gamble) has long term adverse effects on bone mineralization. However, these studies did not suggest the use of other bisphosphonates including alendronate.
There are situations where a female patient is undergoing estrogen therapy for a menopausal or postmenopausal-related condition, (e.g., vasomotor symptoms, atrophy of the vaginal mucosa, increased cardiovascular risk, etc.) and is also discovered to be suffering from osteoporosis (i.e. rarefaction of bone) or to be at risk for developing osteoporosis.
Although estrogens/hormone replacement therapy (HRT) are known to help prevent the development of osteoporosis, there are instances, which are not at all uncommon, where HRT or a weak estrogen is prescribed at dosages which do not provide adequate protection against osteoporosis. There are also some women who continue to lose bone mass despite treatment with higher estrogen/HRT doses or who have established osteoporosis but fail to increase their bone mass on estrogen/HRT alone.
What is desired in these cases is a therapy to optimally treat both the menopausal and postmenopausal-related conditions and the development of osteoporosis or osteoporosis risk concurrently.
SUMMARY OF THE INVENTION
The present invention discloses a combination method for treating and/or preventing bone loss in a subject by the combination therapy of pharmaceutically effective amounts of estrogen and of a bisphosphonate selected from: alendronate, clodronate, tiludronate, YM 175, BM 210995, or mixture thereof.
Also described is a pharmaceutical composition containing the combination described above in a pharmaceutically acceptable carrier. DETAILED DESCRIPTION OF THE INVENTION AND
PREFERRED EMBODIMENTS
By the term "estrogen" as used herein is meant "17-beta estradiol" and includes those equivalent materials contained in the MERCK INDEX - Eleventh Edition (1989). Estrogens, e.g. estradiol and its steroidal and non-steroidal equivalents which can be used herein include (page numbers taken from the above indicated MERCK INDEX):
ESTROGEN
Nonsteroidal
Benzestrol, 1082 Broparoestrol, 1438 Chlorotrianisene, 2173 Dienestrol, 3094 Diethylstilbestrol, 31 18 Diethylstilbestrol Dipropionate, 31 19 Dimestrol, 3198 Fosfestrol, 4168 Hexestrol, 4621 Methallenestril, 5856 Methestrol, 5888 Tamoxifen, 9019
Steroidal
Colpormon, 2485
Conjugated Estrogenic Hormones, 2504
Equilenin, 3581
Equilin, 3582
Estradiol, 3653 Estradiol Benzoate, 3655 Estradiol 17β-Cypionate, 3656 Estriol, 3659 Estrone, 3660 Ethinyl Estradiol, 3689 Mestranol, 5819 Moxestrol, 6203 Mytatrienediol, 6254 Progesterone, 7783 Quinestradiol, 8065 Quinestrol, 8066 and including estrogen/progestin combinations.
By the term "bisphosphonates" as used herein is meant bisphosphonates of the structure:
R2 - C (P03H)2 Rl
in which Rl is OH or H and R2 is an C1 -C5 linear, branched or cyclic alkyl or alkylidene which can be substituted by an terminal amino, substituted amino, e.g. dimethylamino, methylamino, ethylamino, heterocyclic amino, and the like. Also included within the term "bisphosphonates" are the bisphosphonates described above, and those in the US Patents 4,732,998; 4,870,063; 5,130,304 to Leo Pharmaceuticals. Excluded from this category is risedronate.
The method can be used to treat subjects in general, including sport, pet, and farm animals, and humans.
The term "inhibition of bone resoφtion" refers to prevention of bone loss, especially the inhibition of removal of existing bone either from the mineral phase and/or the organic matrix phase, through direct or indirect alteration of osteoclast formation or activity. Thus, the term "inhibitor of bone resoφtion" as used herein refers to agents that prevent bone loss by the direct or indirect alteration of osteoclast formation or activity. The term "osteogenically effective" means that amount which effects the turnover of mature bone. As used herein, an osteogenically effective dose is also "pharmaceutically effective."
The term "subject" as used herein refers to a living vertebrate animal such as a mammal or bird in need of treatment, i.e., in need of bone repair or replacement. Such need arises locally in cases of bone fracture, non-union, defect, prosthesis implantation, and the like. Such need also arises in cases of systemic bone disease, as in osteoporosis, osteoarthritis, Paget's disease, osteomalacia, multiple myeloma and other forms of cancer, steroid therapy, and age-related loss of bone mass. Particularly preferred is a human female subject.
The term "treatment" or "treating" as used herein shall mean (1 ) providing a subject with an amount of a substance sufficient to act prophylactically to prevent the development of a weakened and/or unhealthy state; and/or (2) providing a subject with a sufficient amount of a substance so as to alleviate or eliminate a disease state and/or the symptoms of a disease state, and a weakened and/or unhealthy state.
METHOD OF USE
Drugs which prevent bone loss and/or add back lost bone may be evaluated in the ovariectomized rat. This animal model is well established in the art (see, for example, Wronski, et al. (1985) Calcif. Tissue Int. 37:324-328; Kimmel, et al. (1990) Calcif. Tissue Int. 46:101-1 10; and Durbridge, et al. (1990) Calcif. Tissue Int 47:383-387; these references are hereby incoφorated in their entirety). Wronski, et al. ((1985) Calcif. Tissue Int. 43: 179-183)) describe the association of bone loss and bone turnover in the ovariectomized rat.
Pharmaceutical formulations of the invention which include a bone growth factor and/or an inhibitor of bone resoφtion for administration will generally include an osteogenically effective amount of the bone growth factor to promote bone growth, in addition to a pharmaceutically acceptable excipient. Suitable excipients include most carriers approved for parenteral administration, including water, saline, Ringer's solution, Hank's solution, and solutions of glucose, lactose, dextrose, ethanol, glycerol, albumin, and the like. These compositions may optionally include stabilizers, antioxidants, antimicrobials, preservatives, buffering agents, surfactants, and other accessory additives. The inhibitor of bone resoφtion may also be delivered in a sustained release form from a suitable carrier.
A presently preferred vehicle comprises about 1 mg/ml serum albumin (species-specific) in phosphate-buffered saline (PBS) or isotonic citrate buffer. A thorough discussion of suitable vehicles for parenteral administration may be found in E. W. Martin. "Remington's Pharmaceutical Sciences" (Mack Pub. Co., current edition sections relating to the excipient vehicles and formulating being incoφorated herein by reference to disclose such). Such formulations are generally known to those skilled in the art and are administered systemically to provide systemic treatment.
The estrogen and bisphosphonate may be administered sequentially or concurrently in separate dosages or as a single composition to the subject. If administered sequentially, the period between the administration of the estrogen and bisphosphonate will typically be one week to one year, and optimally, one week to six months.
If the estrogen and bisphosphonate are administered as a single composition, the molar ratio of the estrogen and bisphosphonate will be about 50: 1 to 1 :50, preferably, 5:1 to 1 :5. The optimal ratio is expected to vary from compound to compound. Furthermore, if administered as a single composition the estrogen and bisphosphonate may be separate components of the composition, or they may be conjugated to each other. Methods for conjugating bone growth factors to other agents are described above.
The precise dosage necessary will vary with the age, size, sex and condition of the subject, the nature and severity of the disorder to be treated, and the like; thus, a precise effective amount cannot be specified in advance and will be determined by the caregiver. However, appropriate amounts may be determined by routine experimentation with animal models, as described below. In general terms, an effective dose of estrogen for systemic treatment will range from about 0.001 μg/kg to about 50 μg/kg of body weight and preferably about 30 μg/kg of body weight. An effective dose for biphosphonate is about 1.5 to 3000 μg/kg of body weight and preferably about 10 μg/kg to about 200 μg/kg of body weight.
Effective doses for local administration would be about 0.001 μg to 1 mg per application site.
The methods and compositions of the invention are useful for treating bone fractures defects and disorders which result in weakened bones such as osteoporosis, osteoarthritis, Paget's disease, osteohalisteresis, osteomalacia, bone loss resulting from multiple myeloma other forms of cancer, bone loss resulting from side effects of other medical treatment (such as steroids), and age-related loss of bone mass.
In accordance with one method of use the estrogen and bisphosphonate may be administered systemically either orally and/or parenterally, including subcutaneous or intravenous injection. Additionally, the estrogen and bisphosphonate make be delivered in a slow release form from a suitable carrier.
In accordance with another method of use, the estrogen may be administered locally to a specific area in need of bone growth or repair, with either the concomitant administration of the bisphosphonate at the site, or the administration of the bisphosphonate in a separate vehicle, or the inhibitor of bone resoφtion may be provided locally with the administration of the estrogen in a separate vehicle. Thus, the estrogen and/or bisphosphonate may be implanted directly at the site to be treated, for example, by injection or surgical implantation in a sustained-release carrier. Suitable carriers include hydrogels, controlled- or sustained-release devices (e.g., an Alzet® minipump), polylactic acid, and collagen matrices. Presently preferred carriers are formulations of atelopeptide collagen containing particulate calcium phosphate mineral components, such combinations of homologous or xenographic fibrillar atelopeptide collagen (for example Zyderm® Collagen Implant, available from Collagen Coφoration, Palo Alto, Calif.) with hydroxapatitetricalcium phosphate (HA-TCP, available from Zimmer, Inc., Warsaw, In.). It is presently preferred to administer implant compositions containing and/or an bisphosphonate in a collagen/mineral mixture implant.
Estrogen and/or an bisphosphonate delivered in sustained- release vehicles is also particularly useful for improving implant fixation, for example for improving in growth of new bone into a metal prosthesis in joint reconstruction and dental or orthopedic implants. Alternatively, the estrogen may be delivered in the implant, with the bisphosphonate delivered in a separate vehicle, and vice-versa.
Dental and orthopedic implants can be coated with estrogen in combination with an bisphosphonate to enhance attachment of the implant device to the bone. Alternatively, the estrogen can be used to coat the implant, and the bisphosphonate can be administered concomitantly or sequentially in a separate vehicle, and vice-versa.
In general, implant devices may be coated with a estrogen and/or an bisphosphonate as follows. The estrogen and the bisphosphonate if desired is dissolved at a concentration in the range of 0.01 μg/ml to 200 mg/ml in phosphate-buffered saline (PBS) containing 2 mg/ml serum albumin. The porous end of an implant is dipped in the solution and is airdried (or lyophilized) or implanted immediately into the bony site. The viscosity of the coating solution is increased, if desired, by adding hyaluronate at a final concentration of 0.1 mg/ml to 100 mg/ml or by adding other pharmaceutically acceptable excipients. Alternatively, the solution containing the estrogen (and the bisphosphonate, if desired) is mixed with collagen gel or human collagen (e.g. Zyderm® Collagen Implant, Collagen Coφ., Palo alto, Calif.) to a final collagen concentration of 2 mg/ml to 100 mg/ml to form a paste or gel, which is then used to coat the porous end of the implant device. The coated implant device is placed into the bony site immediately or is airdried and rehydrate with PBS prior to implanting, with the objective of maximizing new bone formation into the implant while minimizing the ingrowth of soft tissue into the implant site. The pharmaceutical compositions according to the present invention containing, e.g., both alendronate and estradiol, may be prepared for use in the form of capsules or tablets or in solution for oral administration or for systemic use. The compositions are advantageously prepared together with inert carriers such as sugars (saccharose, glucose, lactose), starch and derivatives, cellulose and derivatives, gums, fatty acids and their salts, polyalcohols, talc, aromatic esters.
Some typical pharmaceutical formulations containing 4- amino-l-hydroxybutane-l ,l-diphosphonic acid monosodium salt trihydrate are shown here below:
TABLE
Figure imgf000012_0001
EFFERVESCENT GRANULATES
4-amino- 1 -hydroxybutan- 1 ,1 - mg 5.0 mg 10.0 biphosphonic acid Estradiol
Anhydrous Sodium Carbonate Sodium Bicarbonate Anhydrous Citric Acid Sodium Saccharinate Saccharose
Dehydrated Lemon Juice Natural Essence of Lemon
Total Weight
Figure imgf000013_0001
FORMULATIONS SUITABLE FOR INJECTION
4-amino- 1 -hydroxybutan- 1,1 - mg 0.5 mg 1.00 biphosphonic acid Estradiol
Sodium Hydroxide Sodium Chloride Purified Water q h ml
Figure imgf000013_0002

Claims

WHAT IS CLAIMED IS:
1. A method for treating and/or preventing bone loss in a subject, comprising administering a pharmaceutically effective dose of estrogen and a pharmaceutically effective dose of a bisphosphonate selected from the group consisting of: alendronate, clodronate, tiludronate, YM 175, BM 210995, or mixture thereof.
2. The method of Claim 1 wherein the bisphosphonate is alendronate.
3. The method of Claim 1 wherein the subject is human.
4. The method of Claim 1 wherein the estrogen and bisphosphonate are administered sequentially.
5. The method of Claim 1 wherein the estrogen and bisphosphonate are administered concurrently.
6. The method of Claim 1 wherein the bone loss is osteoporosis-related.
7. The method of Claim 1 , wherein the bone loss is due to disuse.
8. The method of Claim 1, wherein the bone loss is age- related.
9. The method of Claim 1 , wherein the bone loss is related to steroid therapy.
10. The method of Claim 1 , wherein the bone loss is rheumatoid-related.
1 1. The method of Claim 1 , wherein the bone loss is related to Paget's disease.
12. The method of Claim 1 , wherein the bone loss is related to cancer.
13. The method of Claim 12, wherein the cancer is multiple myeloma.
14. The method of Claim 1 , wherein the treatment is prophylactic.
15. A composition for inducing net bone formation in a subject, comprising a pharmaceutically effective dose of estrogen and a pharmaceutically effective amount of a bisphosphonate selected from the group consisting of: alendronate, clodronate, YM175, BM 210995, or a mixture thereof.
16. The composition of Claim 15, wherein the molar ratio of estrogen to bisphosphonate, is 50:1 to 1:50.
17. The composition of Claim 15, wherein the molar ratio of estrogen to bisphosphonate, is 5:1 to 1 :5.
18. The composition of Claim 15, wherein the estrogen is conjugated to the bisphosphonate.
19. The composition of Claim 15, further comprising a sustained-release vehicle.
PCT/US1993/012302 1992-12-23 1993-12-17 Bisphosphonate/estrogen therapy for treating and preventing bone loss WO1994014455A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP6515312A JPH08505142A (en) 1992-12-23 1993-12-17 Bisphosphonate / estrogen therapy for treating and preventing bone loss
AU59538/94A AU5953894A (en) 1992-12-23 1993-12-17 Bisphosphonate/estrogen therapy for treating and preventing bone loss
EP94905419A EP0675723A4 (en) 1992-12-23 1993-12-17 Bisphosphonate/estrogen therapy for treating and preventing bone loss.
US08/880,735 US6399592B1 (en) 1992-12-23 1997-06-23 Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99641892A 1992-12-23 1992-12-23
US996,418 1992-12-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US49184695A Continuation-In-Part 1992-12-23 1995-06-22

Publications (1)

Publication Number Publication Date
WO1994014455A1 true WO1994014455A1 (en) 1994-07-07

Family

ID=25542895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/012302 WO1994014455A1 (en) 1992-12-23 1993-12-17 Bisphosphonate/estrogen therapy for treating and preventing bone loss

Country Status (5)

Country Link
EP (1) EP0675723A4 (en)
JP (1) JPH08505142A (en)
AU (1) AU5953894A (en)
CA (1) CA2151240A1 (en)
WO (1) WO1994014455A1 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028936A1 (en) * 1994-04-21 1995-11-02 Merck & Co., Inc. Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis
EP0744176A2 (en) * 1995-05-23 1996-11-27 Eli Lilly And Company Methods for inhibiting bone loss
EP0777484A1 (en) * 1994-08-24 1997-06-11 Merck & Co. Inc. Intravenous alendronate formulations
EP0792639A1 (en) * 1996-02-28 1997-09-03 Pfizer Inc. Combination therapy to treat osteoporosis or conditions which present low bone mass
EP0792645A1 (en) * 1996-02-28 1997-09-03 Pfizer Inc. Combination therapy to treat osteoporosis
WO1997044017A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Effervescent bisphosphonate formulation
EP0824341A1 (en) * 1995-05-12 1998-02-25 Merck & Co., Inc. Prevention of tooth loss by the administration of alendronate or its salts
EP0831844A1 (en) * 1995-06-06 1998-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
WO1998051314A1 (en) * 1997-05-09 1998-11-19 Roche Diagnostics Gmbh Use of diphosphonic acids or the physiologically acceptable salts or esters thereof in the preventive treatment of after-effects resulting from enlargement or replacement of the bladder
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
EP0949928A1 (en) * 1996-11-25 1999-10-20 Merck & Co., Inc. Androgenic and bisphosphonic agents coadministered to treat diseases
EP0998934A1 (en) * 1997-12-25 2000-05-10 Toray Industries, Inc. Remedies for intramedullary diseases
WO2000033849A1 (en) * 1998-12-04 2000-06-15 Roche Diagnostics Gmbh Use of ibandronate for promoting osseointegration of endoprostheses
WO2000064516A1 (en) * 1999-04-22 2000-11-02 Hydromed Sciences A Division Of Gp Strategies Corporation Controlled delivery of bisphosphonates
FR2803521A1 (en) * 2000-01-12 2001-07-13 Ceva Sante Animale Use of tiludronic acid for the prevention and treatment of osteoporosis in laying hens
CN1079671C (en) * 1994-07-22 2002-02-27 伊莱利利公司 Combination treatment for inhibiting bone loss
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
EP1214079A1 (en) * 1999-08-19 2002-06-19 The Royal Alexandra Hospital for Children Drug for treating fractures
WO2002098307A1 (en) * 2001-06-07 2002-12-12 The Royal Alexandra Hospital For Children A device for the delivery of a drug to a fractured bone
EP1365769A1 (en) * 2001-02-06 2003-12-03 The Royal Alexandra Hospital for Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
EP1378234A1 (en) * 1996-05-17 2004-01-07 MERCK & CO. INC. Effervescent bisphosphonate formulation
EP1383509A1 (en) * 2001-04-03 2004-01-28 The Royal Alexandra Hospital for Children A drug for use in bone grafting
EP1508343A1 (en) * 2003-08-21 2005-02-23 ASPENBERG, Per Vilhelm Bisphosponate coated implant device and method therefor
WO2007048264A1 (en) * 2005-10-27 2007-05-03 Thommen Medical Ag Dental implant and production method for said implant
US7611722B2 (en) 2001-12-24 2009-11-03 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US7612052B2 (en) 2001-07-19 2009-11-03 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US7964212B2 (en) 2002-03-06 2011-06-21 Christer Rosen Effervescent compositions comprising phosphonates and methods related thereto
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0697890A1 (en) * 1993-05-15 1996-02-28 Roche Diagnostics GmbH More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927814A (en) * 1986-07-11 1990-05-22 Boehringer Mannheim Gmbh Diphosphonate derivatives, pharmaceutical compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029499A1 (en) * 1990-09-18 1992-03-19 Boehringer Mannheim Gmbh NEW 17- (BETA) -OESTRADIOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
EP0496520A1 (en) * 1991-01-22 1992-07-29 Merck & Co. Inc. Novel bone acting agents
HU215124B (en) * 1991-02-26 1998-09-28 Norwich Eaton Pharmaceuticals, Inc. Process for producing synergetic pharmaceutical compositions containing estrogen and diphosphonate for treating osteoporosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927814A (en) * 1986-07-11 1990-05-22 Boehringer Mannheim Gmbh Diphosphonate derivatives, pharmaceutical compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0675723A4 *

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197213A2 (en) * 1994-04-21 2002-04-17 MERCK & CO. INC. Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis
US5972913A (en) * 1994-04-21 1999-10-26 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
EP1197213A3 (en) * 1994-04-21 2002-09-25 MERCK & CO. INC. Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US5891863A (en) * 1994-04-21 1999-04-06 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
WO1995028936A1 (en) * 1994-04-21 1995-11-02 Merck & Co., Inc. Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis
CN1079671C (en) * 1994-07-22 2002-02-27 伊莱利利公司 Combination treatment for inhibiting bone loss
US5914323A (en) * 1994-08-24 1999-06-22 Merck & Co., Inc. Intravenous alendronate formulations
EP0777484A4 (en) * 1994-08-24 1998-08-05 Merck & Co Inc Intravenous alendronate formulations
US5843924A (en) * 1994-08-24 1998-12-01 Merck & Co., Inc. Intravenous alendronate formulations
EP0777484A1 (en) * 1994-08-24 1997-06-11 Merck & Co. Inc. Intravenous alendronate formulations
JP2004075690A (en) * 1994-08-24 2004-03-11 Merck & Co Inc Alendronate composition for intravenous infusion
EP0824341A1 (en) * 1995-05-12 1998-02-25 Merck & Co., Inc. Prevention of tooth loss by the administration of alendronate or its salts
EP0824341A4 (en) * 1995-05-12 1999-07-07 Merck & Co Inc Prevention of tooth loss by the administration of alendronate or its salts
EP0744176A2 (en) * 1995-05-23 1996-11-27 Eli Lilly And Company Methods for inhibiting bone loss
EP0744176A3 (en) * 1995-05-23 2002-05-15 Eli Lilly And Company Methods for inhibiting bone loss
EP0831844A1 (en) * 1995-06-06 1998-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
EP0831844A4 (en) * 1995-06-06 1998-12-30 Merck & Co Inc Bisphosphonates prevent bone loss associated with immunosuppressive therapy
EP0792645A1 (en) * 1996-02-28 1997-09-03 Pfizer Inc. Combination therapy to treat osteoporosis
EP0792639A1 (en) * 1996-02-28 1997-09-03 Pfizer Inc. Combination therapy to treat osteoporosis or conditions which present low bone mass
WO1997044017A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Effervescent bisphosphonate formulation
EP1378234A1 (en) * 1996-05-17 2004-01-07 MERCK & CO. INC. Effervescent bisphosphonate formulation
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
JP2009167200A (en) * 1996-05-17 2009-07-30 Merck & Co Inc Effervescent bisphosphonate formulation
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
EP0949928A1 (en) * 1996-11-25 1999-10-20 Merck & Co., Inc. Androgenic and bisphosphonic agents coadministered to treat diseases
EP0949928A4 (en) * 1996-11-25 2000-09-13 Merck & Co Inc Androgenic and bisphosphonic agents coadministered to treat diseases
US6476008B1 (en) 1997-05-09 2002-11-05 Roche Diagnostics Gmbh Use of diphosphonic acids or the physiologically acceptable salts or esters thereof in the preventive treatment of after-effects resulting from enlargement or replacement of the bladder
WO1998051314A1 (en) * 1997-05-09 1998-11-19 Roche Diagnostics Gmbh Use of diphosphonic acids or the physiologically acceptable salts or esters thereof in the preventive treatment of after-effects resulting from enlargement or replacement of the bladder
EP0998934A4 (en) * 1997-12-25 2005-09-14 Toray Industries Remedies for intramedullary diseases
EP0998934A1 (en) * 1997-12-25 2000-05-10 Toray Industries, Inc. Remedies for intramedullary diseases
WO2000033849A1 (en) * 1998-12-04 2000-06-15 Roche Diagnostics Gmbh Use of ibandronate for promoting osseointegration of endoprostheses
EP1614422A3 (en) * 1998-12-04 2009-02-18 Boehringer Mannheim Gmbh Ibandronate for the promotion of osseointegration of endoprostheses
US6680307B1 (en) 1998-12-04 2004-01-20 Roche Diagnostics Gmbh Use of ibandronate for promoting osseointegration of endoprostheses
WO2000064516A1 (en) * 1999-04-22 2000-11-02 Hydromed Sciences A Division Of Gp Strategies Corporation Controlled delivery of bisphosphonates
EP1214079A1 (en) * 1999-08-19 2002-06-19 The Royal Alexandra Hospital for Children Drug for treating fractures
EP1214079A4 (en) * 1999-08-19 2004-03-24 Royal Alexandra Hosp Children Drug for treating fractures
FR2803521A1 (en) * 2000-01-12 2001-07-13 Ceva Sante Animale Use of tiludronic acid for the prevention and treatment of osteoporosis in laying hens
EP1129714A1 (en) * 2000-01-12 2001-09-05 Ceva Sante Animale Use of tiludronic acid and its derivatives in poultry for the preparation of a medicine for preventing and treating osteoporosis
US6482809B1 (en) 2000-01-12 2002-11-19 Ceva Sante Animale Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis
EP1365769A1 (en) * 2001-02-06 2003-12-03 The Royal Alexandra Hospital for Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
US7425549B2 (en) 2001-02-06 2008-09-16 The Royal Alexandra Hospital For Children Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
EP1365769A4 (en) * 2001-02-06 2005-08-10 Royal Alexandra Hosp Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
EP1383509A4 (en) * 2001-04-03 2005-10-26 Royal Alexandra Hosp Children A drug for use in bone grafting
EP1383509A1 (en) * 2001-04-03 2004-01-28 The Royal Alexandra Hospital for Children A drug for use in bone grafting
WO2002098307A1 (en) * 2001-06-07 2002-12-12 The Royal Alexandra Hospital For Children A device for the delivery of a drug to a fractured bone
US7612052B2 (en) 2001-07-19 2009-11-03 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US8008330B2 (en) 2001-07-19 2011-08-30 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US7611722B2 (en) 2001-12-24 2009-11-03 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US7964212B2 (en) 2002-03-06 2011-06-21 Christer Rosen Effervescent compositions comprising phosphonates and methods related thereto
US8449906B2 (en) 2002-03-06 2013-05-28 EffRx Pharmaceuticals, S.A. Effervescent compositions comprising phosphonates and methods related thereto
WO2005018699A1 (en) * 2003-08-21 2005-03-03 Optovent Ab Bisphosphonate coated implant device and method therefor
CN1871038B (en) * 2003-08-21 2010-10-06 艾德拜奥股份有限公司 Bisphosphonate coated implant device and method therefor
EP1508343A1 (en) * 2003-08-21 2005-02-23 ASPENBERG, Per Vilhelm Bisphosponate coated implant device and method therefor
WO2007048264A1 (en) * 2005-10-27 2007-05-03 Thommen Medical Ag Dental implant and production method for said implant
US8940320B2 (en) 2005-10-27 2015-01-27 Thommen Medical Ag Dental implant and production method for said implant
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Also Published As

Publication number Publication date
EP0675723A4 (en) 1998-08-05
JPH08505142A (en) 1996-06-04
EP0675723A1 (en) 1995-10-11
CA2151240A1 (en) 1994-07-07
AU5953894A (en) 1994-07-19

Similar Documents

Publication Publication Date Title
EP0675723A1 (en) Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5972913A (en) Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
EP0635270B1 (en) Parathyroid hormone and raloxifene for increasing bone mass
Harris et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women
US20040097468A1 (en) Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
US6399592B1 (en) Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
US6376477B2 (en) Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
AU701258B2 (en) Bone mass anabolic composition comprising olpadronate
AU743121B2 (en) Androgenic and bisphosphonic agents coadministered to treat diseases
AU2005203308A1 (en) Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis
MXPA96004968A (en) Use of bisphosphonates to inhibit bone rebassion after the implantation of orthopedic protesis
AU9745901A (en) Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis
AU3574799A (en) Use of biphosphonates for inhibiting bone resorption following implantation of orthopedic prosthesis
Forde Pharmacological Intervention in the Treatment of Osteoporosis: What's Old and What's New

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA US UZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2151240

Country of ref document: CA

Ref document number: 1994905419

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1995 491846

Country of ref document: US

Date of ref document: 19950622

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1994905419

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1994905419

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994905419

Country of ref document: EP